||
近期,一项发表在《Trends in Cancer》期刊的一篇综述总结了接受HER2靶向治疗的乳腺癌等实体瘤中HER2异质性的生物学和临床意义的证据,并为提升HER2异质性评估方法和HER2异质性肿瘤的治疗策略进行介绍[2]。特此整理乳腺癌相关重点内容,以飨读者。
https://kns.cnki.net/kns8s/search
(276)
(159)
(70)
(54)
(49)
(49)
(46)
(46)
(44)
(43)
http://www.pubmedplus.cn/P/SearchQuickResult?wd=dfdb3677-7727-4d8d-bb31-de459ccf8608
01. | Breast Neoplasms | 5 篇 | 0.062% |
02. | Female | 5 篇 | 0.062% |
03. | Humans | 5 篇 | 0.062% |
04. | Middle Aged | 4 篇 | 0.050% |
05. | Trastuzumab | 4 篇 | 0.050% |
06. | Adult | 3 篇 | 0.037% |
07. | Aged | 3 篇 | 0.037% |
08. | Prognosis | 3 篇 | 0.037% |
09. | Receptor, ErbB-2 | 3 篇 | 0.037% |
10. | Survival Rate | 3 篇 | 0.037% |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-11-23 04:13
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社